At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
NIDO-361 +1 moredrug
Likely dose
NIDO-361 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
In Brief
A Phase 2 clinical trial evaluating NIDO-361 and Placebo for Spinal and Bulbar Muscular Atrophy and Kennedy's Disease. Completed, enrolled 54 participants across 5 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Italy, South Korea, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
Enrollment StartMar 2024
First PostedMay 2024
Primary CompletionOct 2025
TodayJul 2026
First PostedMay 13, 2024
Enrollment StartMar 1, 2024
Primary CompletionOct 22, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.1 years ago
Interventions
NIDO-361drug
Tablets containing 100mg of NIDO-361 for oral administration.
Placebodrug
Placebo oral tablets